Evidence map›Paper›PMID 24652407›Full record

ReviewProtoplasma2014

Microtubule drugs: action, selectivity, and resistance across the kingdoms of life.

V Dostál, L Libusová

Abstract readReview
PubMed Publisher
In one paragraph

Review in Protoplasma, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Molecular sensors reveal the mechano-chemical response ofCell surface (Amsterdam, Netherlands) · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Alpha-Tubulin Acetylation inFrontiers in cellular and infection microbiology · 2021
    Article
  13. Article
  14. In vivo comparison of N-Bioorganic & medicinal chemistry letters · 2020
    Article
  15. Review
  16. Article
  17. Article
  18. Radiosynthesis and in Vivo Evaluation of [Journal of medicinal chemistry · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

V DostálDepartment of Cell Biology, Faculty of Science, Charles University in Prague, Viničná 7, 128 43, Prague 2, Czech Republic.
L Libusová
Charles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microtubule drugs such as paclitaxel, colchicine, vinblastine, trifluralin, or oryzalin form a chemically diverse group that has been reinforced by a large number of novel compounds over time. They all share the ability to change microtubule properties. The profound effects of disrupted microtubule systems on cell physiology can be used in research as well as anticancer treatment and agricultural weed control. The activity of microtubule drugs generally depends on their binding to α- and β-tubulin subunits. The microtubule drugs are often effective only in certain taxonomic groups, while other organisms remain resistant. Available information on the molecular basis of this selectivity is summarized. In addition to reviewing published data, we performed sequence data mining, searching for kingdom-specific signatures in plant, animal, fungal, and protozoan tubulin sequences. Our findings clearly correlate with known microtubule drug resistance determinants and add more amino acid positions with a putative effect on drug-tubulin interaction. The issue of microtubule network properties in plant cells producing microtubule drugs is also addressed.

Indexed as

AnimalsFungiHumansMicrotubulesPlantsSpecies SpecificityTaxoidsTubulinTubulin ModulatorsVinca AlkaloidsTaxoidsTubulinTubulin ModulatorsVinca Alkaloids

Identifiers

PMID24652407
OpenAlexW2144874262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.